Multiple Myeloma Perspective

 
 
  • EHA 2021 Read clinically focused news coverage of key developments from EHA 2021
  • MGUS, SPEP, and the Shaka Sign   With the right threshold of suspicion, a patient's life may be saved.
  • Advances in Multiple Myeloma From ASH 2020   Breakthroughs in multiple myeloma from ASH 2020 include transplant studies in newly diagnosed patients, triple therapy in early relapse, and CAR T-cell as well as bispecific therapy in later relapse.
  • Myeloma-Induced Acute Kidney Injury: Medicine vs Machine Higher-tech or more aggressive treatment doesn't necessarily mean better, cautions Tejas Desai, MD, in his review of studies on treatment strategies for myeloma-induced acute kidney injury.
  • IWMF 2020 Read clinically focused news coverage of key developments from IWMF 2020
  • EHA 2020 Read clinically focused news coverage of key developments from EHA 2020
  • Smoldering Multiple Myeloma: Dangerous Precursor: What the Future Brings   Hematologists look to the future and ask: Given the growing array of therapeutic options, which strategies will become standard practice in smoldering myeloma?
  • Smoldering Multiple Myeloma: Dangerous Precursor: Come Out Fighting   Hematologists from MSKCC report on results of small trials that suggest that treating high-risk smoldering myeloma aggressively may cure the disease.
  • Smoldering Multiple Myeloma: Dangerous Precursor: Micro Assault   Winship experts discuss the role of the immune system in preventing the progression to myeloma, as suggested by findings in the ECOG-E3A06 trial and other data.
  • A 62-Year-Old Man Who Demands Testing A 62-year-old man who has no acute complaints demands testing for multiple myeloma, due to his father's death. What do his test results show?
  • Updated Pneumococcal Vaccine Recommendations for Older Adults   What do the new PCV13 recommendations mean, and how do you implement them in your practice? Here's what you need to know.
  • Smoldering Multiple Myeloma: Dangerous Precursor: Risk Can Change   Data show that patients with high-risk SMM benefit most from therapy, but risk can change over time, and intermediate-risk patients should be monitored regularly.
  • Top News From ASH 2019: Slideshow Highlights include the exciting prospect of an off-the-shelf product to rival CAR T cells, practice-changing studies on two leukemias, plus 'Choosing Wisely' advice for children.
  • CAR T-Cell Highlights From the 2019 ASH Annual Meeting   Dr Michael Bishop highlights new CAR T-cell therapies presented at the 2019 ASH annual meeting that are likely to garner approvals in the near future.
  • Top Stories in Multiple Myeloma From ASH 2019   Dr Joseph Mikhael highlights data on front-line therapy in multiple myeloma that indicate benefit from the addition of daratumumab to standard induction combinations, as presented at ASH 2019.
  • Smoldering Multiple Myeloma: Dangerous Precursor: Treatment or Prevention?   Winship experts discuss treatment versus prevention in patients with smoldering myeloma as well as the results of the ECOG-E3A06 trial, led by Dr Sagar Lonial.
  • Smoldering Multiple Myeloma: Dangerous Precursor   Revised criteria for multiple myeloma and an array of effective, well-tolerated myeloma drugs have prompted hematologists to assess the benefit of treating smoldering multiple myeloma.
  • Top News From ASCO 2019: Slideshow Highlights include potentially practice-changing data on immunotherapy for head and neck cancer, as well new data for breast, lung, prostate and pancreatic cancer.
  • EHA 2019 Read clinically focused news coverage of key developments from EHA 2019
  • 'Mind-boggling' IO Data, Plus New Combos, Targets for NSCLC   Drs West, Aggarwal, and Patel discuss the 'mind-boggling,' 'humbling,' and 'amazing' advances in survival statistics and targeted therapies for NSCLC presented at ASCO 2019.